Triple threat: new CAR t-cells take on Hard-to-Treat lymphomas
NCT ID NCT07168486
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 34 times
Summary
This early-phase study tests a new type of CAR T-cell therapy that targets three different markers on cancer cells (CD19, CD20, and CD22) to treat people with B-cell lymphomas that have come back or not responded to standard treatments. About 15 adults will receive these specially engineered immune cells to see if they are safe and effective. The goal is to improve cancer control and reduce the chance of relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Maryland, Baltimore
Baltimore, Maryland, 21201, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.